Department of Gastroenterology, The Royal Wolverhampton NHS Trust, Wolverhampton, UK
Inflammatory Bowel Disease Unit, Guys and St Thomas' NHS Foundation Trust, London, UK.
BMJ Open Gastroenterol. 2022 Jan;9(1). doi: 10.1136/bmjgast-2021-000759.
The WHO has recognised iron deficiency anaemia (IDA) as the most common nutritional deficiency in the world, with 30% of the population being affected with this condition. Although the most common causes of IDA are gastrointestinal bleeding and menstruation in women, decreased dietary iron and decreased iron absorption are also culpable causes. Patients with IDA should be treated with the aim of replenishing iron stores and returning the haemoglobin to a normal level. This has shown to improve quality of life, morbidity, prognosis in chronic disease and outcomes in pregnancy. Iron deficiency occurs in many chronic inflammatory conditions, including congestive cardiac failure, chronic kidney disease and inflammatory bowel disease. This article will provide an updated overview on diagnosis and management of IDA in patients with chronic conditions, preoperative and in pregnancy. We will discuss the benefits and limitations of oral versus intravenous iron replacement in each cohort, with an overview on cost analysis between the different iron formulations currently on the market.
世界卫生组织已将缺铁性贫血(IDA)确认为世界上最常见的营养缺乏症,全球有 30%的人患有这种疾病。虽然 IDA 最常见的原因是胃肠道出血和女性月经,但膳食铁减少和铁吸收减少也是导致这种疾病的原因。IDA 患者应进行治疗,以补充铁储存并将血红蛋白恢复到正常水平。这已显示出改善生活质量、发病率、慢性病预后和妊娠结局。缺铁发生在许多慢性炎症性疾病中,包括充血性心力衰竭、慢性肾脏病和炎症性肠病。本文将提供关于慢性疾病患者、术前和妊娠期间 IDA 的诊断和管理的最新概述。我们将讨论口服与静脉铁替代在每个队列中的益处和局限性,并概述目前市场上不同铁制剂之间的成本分析。